Encore Vision's Series A - II Round

Encore Vision raised a round of funding on September 17, 2014. Investors include Steelhead Capital Management.

Encore Vision (EV) develops EV06, a clinical-stage, disease-modifying topical therapy for presbyopia. EV06 comprises a proprietary small molecule prodrug, which works with the eye's endogenous enzymes…

Articles about Encore Vision's Series A - II Round: